MOTS-c: a peptide encoded by the mitochondrial genome, and what the thin human evidence says

Almost every peptide sold as research material is a fragment of something your nucleus encodes. MOTS-c is not. It is written into mitochondrial DNA — inside the 12S ribosomal RNA gene, in a short open reading frame that was not supposed to be there — and it is one of only a handful of such peptides known. That is the genuinely unusual thing about it, and it is a fact about genetics rather than a claim about anything.

The literature that follows from it is small, concentrated in a few laboratories, and almost entirely preclinical. There is no approval anywhere and no controlled human trial of the peptide as an intervention. Here is what has actually been done.

Where it came from

Mitochondria carry their own small circular genome, understood for decades to encode only a handful of respiratory-chain proteins. Then humanin was identified in a mitochondrial short open reading frame, which raised the obvious question: if there is one, are there others?

In 2015 Lee and colleagues reported a second. Within the mitochondrial 12S rRNA they found a short open reading frame encoding a 16–amino acid peptide, which they named MOTS-c — mitochondrial open reading frame of the 12S rRNA-c (PMID 25738459). The paper's framing is the part worth keeping: mitochondria are not only metabolic machinery but a signalling unit, sending instructions outward using peptides encoded in their own genome. That is retrograde signalling, mitochondrion to nucleus — a direction of information flow cell biology took a long time to take seriously.

What the mechanism work describes

The 2015 paper placed MOTS-c's cellular action in the folate cycle and the de novo purine synthesis tethered to it. Inhibiting that pathway causes an intermediate to accumulate, and that intermediate activates AMPK — the kinase that reads cellular energy status and shifts metabolism towards fuel oxidation when it falls. Skeletal muscle appeared to be the primary target organ. In mice, the paper reported that treatment prevented age-dependent and high-fat-diet-induced insulin resistance, and diet-induced obesity.

For most of the following decade the receptor or direct target was unidentified, which is a serious limitation for any compound: without a target you cannot predict what else it touches. That changed in 2024, when Kumagai and colleagues reported that MOTS-c binds casein kinase 2 (CK2) directly and that CK2 activity is required for its effects in mice (PMID 39559755). The same paper reported that the effect is tissue-specific — the peptide bound CK2 in both fat and muscle but activated it in muscle while suppressing it in fat — and that a naturally occurring variant with reduced CK2 binding did not produce the effects. That is a meaningful step towards a mechanism, and it is four years newer than most of what gets quoted about this peptide.

The exercise thread

Reynolds and colleagues reported in 2021 that MOTS-c expression in skeletal muscle and in circulation is induced by exercise in humans, and examined administration in mice at 2, 12 and 22 months of age (PMID 33473109). The mouse work reported increased physical performance across those ages, effects on nuclear gene expression related to metabolism and proteostasis, and increased physical capacity when intermittent treatment was initiated late in life.

This is where the phrase "exercise mimetic" enters the literature, and it needs reading carefully. It describes an overlap in transcriptional response between the peptide and exercise in a model organism. It is not a finding that anything substitutes for exercise in a person, and no published work tests that.

The human half of that paper is the measurement half: exercise raises endogenous MOTS-c. That is an observation about a biomarker, not an intervention.

The human evidence, and exactly what kind it is

All of the human MOTS-c literature is observational. Two threads carry it.

Measurement. Circulating MOTS-c has been measured as a marker across ageing and around exercise in various cohorts. These studies report associations with an endogenous peptide concentration. None administers the peptide.

Genetics. Within the MOTS-c reading frame there is an East Asian–specific polymorphism, m.1382A>C, which changes the fourteenth residue and produces a variant known as K14Q with less biological activity. Fuku and colleagues proposed in 2015 that this variant might be among the mechanisms behind exceptional longevity in Japanese populations (PMID 26289118) — proposed, explicitly, as a hypothesis in a short commentary, not demonstrated. Kumagai and colleagues later examined the same polymorphism against muscle fibre composition and performance in Japanese cohorts, reporting that C-allele carriers showed a higher proportion of fast-twitch myosin heavy chain, that men carrying it produced higher peak leg torques, and that allele frequency was higher in sprint and power athletes than in endurance athletes (PMID 34728329).

Genetic association studies of this kind are informative about biology and weak as evidence about a compound. A variant that alters a peptide's activity over a lifetime, in a population with shared ancestry, tells you the peptide matters. It tells you nothing about what administering it to someone would do.

Where the evidence stops

No controlled human trial of the peptide exists. Not for metabolism, not for muscle, not for ageing. The human data are measurement and genetics.

It is not approved anywhere. Not by Health Canada, the FDA or the EMA, for any indication. There is no licensed product and no registration programme with published results.

The literature is concentrated. A large share of it traces to Pinchas Cohen's group and collaborators, and the authors' own disclosures state that the intellectual property on MOTS-c was licensed by UCLA to a biotechnology company, with senior authors holding advisory and shareholding positions. None of that invalidates the work — the disclosures are there because the journals require them and the authors made them. It does mean independent replication is the thing to look for when reading, and there is not much of it.

Pharmacokinetics in humans are uncharacterised. A 16-residue peptide is short, and how long it survives and where it distributes in a person are open questions with no published answers.

Mouse metabolism is not human metabolism. Diet-induced obesity in a mouse on defined high-fat chow is a tractable model, and it is not a person.

What is supplied here

MOTS-c is supplied as MOTS-c, a lyophilised powder for laboratory use. Janoshik-verified by HPLC with mass-spec identity confirmation; 100% synthetic. The measured purity for each lot is stated on its product page. For laboratory research use only.

Reconstitution is concentration arithmetic: a 10 mg vial taken up in 2 mL of bacteriostatic water gives 5 mg/mL; the same vial in 5 mL gives 2 mg/mL. That is the whole calculation; it implies nothing about use.

For a different and much larger mitochondrial literature, see NAD+ and mitochondrial research, sold here as NAD+. For the other skeletal-muscle metabolic compound in this catalogue, see 5-Amino-1MQ and muscle regeneration research.

Common questions

Can I use this to lose weight? No. What is sold here is a research chemical for laboratory use, not a medicine and not a weight-loss product. The weight and insulin-sensitivity findings in the MOTS-c literature are mouse findings, there has never been a controlled human trial of this peptide, and no regulator has approved it for anything. There is no evidence base about people to act on even if the legal position were different, and it is not.

Is MOTS-c an "exercise mimetic"? That is a term from the papers, and it describes overlapping transcriptional responses in model systems plus the observation that exercise raises the peptide in humans. It is a description of a research finding, not a claim that anything replaces training. Nobody has tested that in a person.

Why does so much of the literature come from one group? Cohen's laboratory identified the peptide and has driven the field since, which is the normal pattern for a newly discovered molecule — the same concentration shows up in the early BPC-157 literature. It is historical rather than suspicious. The practical consequence is that most findings share methods and assumptions, and independent replication is thin.

Is it legal to buy in Canada? It is sold here as a research chemical for laboratory use only. It is not an approved drug in Canada, is not sold for human use, and nothing on this site constitutes medical, dosing or therapeutic guidance.

Selected Research References

1. Lee C, Zeng J, Drew BG, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metabolism. 2015;21(3):443-454. pubmed.ncbi.nlm.nih.gov/25738459
2. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c Is an Exercise-Induced Mitochondrial-Encoded Regulator of Age-Dependent Physical Decline and Muscle Homeostasis. Nature Communications. 2021;12(1):470. pubmed.ncbi.nlm.nih.gov/33473109
3. Kumagai H, Kim SJ, Miller B, et al. MOTS-c Modulates Skeletal Muscle Function by Directly Binding and Activating CK2. iScience. 2024;27(11):111212. pubmed.ncbi.nlm.nih.gov/39559755
4. Kumagai H, Natsume T, Kim SJ, et al. The MOTS-c K14Q Polymorphism in the mtDNA Is Associated with Muscle Fiber Composition and Muscular Performance. Biochimica et Biophysica Acta — General Subjects. 2022;1866(2):130048. pubmed.ncbi.nlm.nih.gov/34728329
5. Fuku N, Pareja-Galeano H, Zempo H, et al. The Mitochondrial-Derived Peptide MOTS-c: A Player in Exceptional Longevity? Aging Cell. 2015;14(6):921-923. pubmed.ncbi.nlm.nih.gov/26289118

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.